Pubblicazioni

Effects of 26âweeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial

2022 - DIABETES, OBESITY AND METABOLISM

Succurro, Elena; Vizza, Patrizia; Papa, Annalisa; Miceli, Sofia; Cicone, Francesco; Fiorentino, Teresa Vanessa; Sciacqua, Angela; Andreozzi, Francesco; Veltri, Pierangelo; Cascini, Giuseppe Lucio; Sesti, Giorgio

Pubblicazioni

Effects of 26âweeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial

Effects of 26âweeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial